Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
EClinicalMedicine (2022) - Comments
pubmed: 35434578  doi: 10.1016/j.eclinm.2022.101383  issn: 2589-5370 

Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, Yenima Martín-Bauta, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Joel Quintana-Guerra, Karen Urrutia-Pérez, Klaudia Urrutia-Pérez, Cristina O. Chávez-Chong, Jorge L. Azor-Hernández, José L. Rodríguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Ávila, Jacqueline Bizet-Almeida, Jeniffer Rodríguez-Nuviola, Sergio Del Valle-Piñera, Mayara Ramírez-Domínguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdés, Gilda Lemos-Pérez